REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo tackles tough lymphoma in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New hope for blood cancer patients after CAR t fails
Disease control CompletedThis study tested a drug called nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab helps the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow …
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:01 UTC
-
New hope for lymphoma patients when CAR T-Cells fail
Disease control CompletedThis study tested a drug called glofitamab in 67 people with lymphoma that did not respond or came back after CAR T-cell therapy. Glofitamab is a bispecific antibody that helps the immune system attack cancer cells. The goal was to see if it could control the disease, not cure it…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated May 12, 2026 13:40 UTC